Philips integrates 3D ultrasound with innovative software for breakthrough in surveillance of abdominal aortic aneurysms
January 27 2021 - 4:00AM
Philips integrates 3D ultrasound with innovative software for
breakthrough in surveillance of abdominal aortic aneurysms
Jan. 27, 2021
Philips Abdominal Aortic Aneurysm (AAA) Model helps increase
diagnostic confidence and improved patient experience compared to
current standard of care
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, has introduced
the Philips Abdominal Aortic Aneurysm (AAA) Model, providing
physicians a more patient-friendly solution compared to the current
standard of care for managing AAA patients. Based on 3D ultrasound,
Philips AAA Model delivers clinicians accurate diagnostic
information without exposing patients to high doses of radiation
and nephrotoxic contrast agents.
An abdominal aortic aneurysm (AAA) is an aneurysm that forms in
the lower part of the aorta. Typically, AAAs are identified
incidentally during abdominal imaging exams but, in some cases,
remain undetected until rupture. A ruptured AAA has an 80%
mortality rate [1], emphasizing the importance of routine
surveillance. Philips AAA Model integrates innovative software and
leading Philips 3D ultrasound technologies into a single solution
to help increase diagnostic confidence and an improved patient
experience. The software automatically segments and quantifies the
size of the aneurysm sac for surveillance of known native
(untreated), and post-EVAR (treated) AAAs.
The current standard of care for AAAs includes 2D ultrasound and
computed tomography angiography (CTA). Each of these modalities has
its drawbacks, including inter-operator variability with 2D
ultrasound and patient exposure to high levels of radiation and
nephrotoxic contrast agents with CTA.
A recent clinical study showed that 3D ultrasound examination
for native AAA surveillance has excellent inter-operator
reproducibility, superior to that of 2D ultrasound, supporting the
broader use of 3D ultrasound in standard AAA surveillance programs
[2]. 3D ultrasound has been shown to estimate the diameter and
volume of an AAA with acceptable reproducibility and an improved
agreement (over 2D ultrasound) with CT [3]. Furthermore, 3D
ultrasound has also been proven to correlate significantly better
to 3D CT than 2D ultrasound for assessing the maximum diameter of
the residual sac post-EVAR, with clinically acceptable
reproducibility [4].
“Regular surveillance of abdominal aortic aneurysm patients is
essential, but today’s standard of care has downsides,” said Bich
Le, Senior Vice President, General Manager Ultrasound at Philips.
“Philips Abdominal Aortic Aneurysm (AAA) Model seamlessly
integrates leading Philips technologies including Philips Premium
Ultrasound System (EPIQ Elite), Philips Array Transducer (X6-1
xMATRIX) and innovative software into a single solution, to help
improve the experience and outcomes for clinicians and patients
alike.”
Launch of Philips Abdominal Aortic Aneurysm (AAA) Model at
LINC 2021Philips will debut the AAA Model at the LINC (Leipzig
Interventional Course) Summit, Europe’s premiere interventional
course for vascular specialists, taking place virtually, Jan.
25-29, 2021. Visit Philips at LINC for more information on
Philips AAA model, including live demos, and follow
@PhilipsLiveFrom for updates throughout the virtual event.
LINC attendees are also invited to attend a Symposium on
Aortic Aneurysms, Friday, Jan. 29 at 12:30 PM CET, where clinicians
will discuss the highest quality of care in complex EVAR procedure
with advanced imaging techniques, from planning to follow-up.
Participating in the Symposium is Prof. Henrik Sillesen who will
address improving AAA measurement accuracy using innovative
Ultrasound 3D volume moderation and xMATRIX.
The Philips Abdominal Aortic Aneurysm (AAA) Model is CE marked
for sale in Europe and is FDA cleared for sale in the U.S.
[1] Age-specific incidence, risk factors, and outcome of acute
abdominal aortic aneurysms in a definedpopulation. Howard DP,
Banerjee A, Fairhead JF, et al. Br J Surg. 2015;102(8):907–915.
doi:10.1002/bjs.9838[2] Clinical validation of three-dimensional
ultrasound for abdominal aortic aneurysm. Ghulam, Qasam M. et
al.,Journal of Vascular Surgery, Volume 71, Issue 1 [3]
Three-dimensional ultrasound evaluation of small asymptomatic
abdominal aortic aneurysms. Bredahl, K. etal. European Journal of
Vascular and Endovascular Surgery, Volume 49, Issue 3, 289 – 296[4]
Three-dimensional ultrasound improves the accuracy of diameter
measurement of the residual sac in EVARpatients. K. Bredahl, M.
Taudorf, A. Long, L. Lönn, L. Rouet, R. Ardon, H. Sillesen, J.P.
Eiberg. European Journalof Vascular and Endovascular Surgery,
Volume 46, Issue 5, 2013
For further information, please contact:
Kathy O’ReillyPhilips Global Press OfficeTel.: +1
978-221-8919E-mail: kathy.oreilly@philips.com Twitter:
@kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 19.5 billion and
employs approximately 82,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips AAA model in progress
- Philips AAA model results
- Philips AAA model
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024